| 研究実績の概要 |
We have identified 20 lasso-grafted peptides, termed “Ubodies”, that target one of the major cancer-drivers, KRas(G12D). Some compounds bind to the protein target with high selectivity towards the cancer-driver “on” state of KRas vs its “off” state; while others are selective towards the mutant form vs its wildtype parent (some compounds exhibit dual selectivity). These Ubodies thus have high potential as therapeutic candidates with very little side-effects. Furthermore, we have also developed a new method to identify de novo highly potent Ubodies without the need for a previous binding peptide, which we are currently applying to other cancer targets. We have also started investigating drug delivery avenues (lipid nanoparticles & gene delivery), and early protocols are being validated.
|
